# AN2 Therapeutics, Inc. (ANTX)

> Source: Nexqual · https://nexqual.com/ANTX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, AN2 Therapeutics, Inc. (ANTX), nexqual.com/ANTX" · informational, not investment advice.

**Price:** USD 3.6 (+1.69% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 3.54 · day 3.5–3.69 · 52w 1–7.19 · market cap $136M · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 9 (range 9–9).
- Total return with dividends: 1Y +205.1% vs S&P 500 +18.1%; 5Y -76.6% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 9 (low 9, high 9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Guggenheim | Initiated | Buy | $9 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2022-03-21) |
|---|---|---|
| Total return | +205.1% | -76.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +206.3% | -27.2% |
| Volatility (annualized) | 111.2% | 136.3% |
| Max drawdown | -45.6% (Mar 2026→Apr 2026) | -95.3% (Jan 2024→Aug 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/ANTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt